PATENT CLAIM ANALYSIS

Application Number: 15742889
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "406000"]

Abstract:
The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine˜2˜carbonitrile and pharmaceutically acceptable salts and solvates thereof that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas.

Claim (Index 1):
A method of treating cancer comprising: administering to a patient in need thereof an effective amount of a compound which is 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, or a pharmaceutically acceptable salt thereof, or a solvate of the pharmaceutically acceptable salt thereof; wherein the cancer is selected from the group consisting of neuroblastoma, rhabdomyosarcoma, osteosarcoma, Ewing's sarcoma, desmoplastic small round cell tumor, and leiomyosarcoma.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 86.0
- Lexical Diversity: 1.26471
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12634725', '15513185', '15118072', '14402198', '11919173']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7353985964250794
- 35 USC 102 Novelty (BERT): 0.5501275551363677
- Combined Prediction Score: 0.7168714922962083
- Mean Citation Score: 303.550176
- Max Citation Score: 394.67114
- Similarity Product: 336.26684427292224

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test